Literature DB >> 16827586

Molecular interactions of dendrimers with amyloid peptides: pH dependence.

B Klajnert1, J Cladera, M Bryszewska.   

Abstract

The formation of amyloid plaques is a key pathological event in neurodegenerative disorders, such as prion and Alzheimer's diseases. Dendrimers are considered promising therapeutic agents in these disorders. In the present work, we have studied the effect of polypropyleneimine dendrimers on the formation of amyloid fibrils as a function of pH in order to gain further insight in the aggregation mechanism and its inhibition. Amyloid fibrils from prion peptide PrP 185-208 and Alzheimer's peptide Abeta 1-28 were produced in vitro, and their formation was monitored using the dye thioflavin T (ThT). The results showed that the level of protonation of His, Glu, and Asp residues is important for the final effect, especially at low dendrimer concentration when their inhibiting capacity depends on the pH. At the highest concentrations, dendrimers were very effective against fibril formations for both prion and Alzheimer's peptides.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16827586     DOI: 10.1021/bm060229s

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  10 in total

Review 1.  Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective.

Authors:  Javed Ahmad; Sohail Akhter; Md Rizwanullah; Mohammad Ahmed Khan; Lucie Pigeon; Richard T Addo; Nigel H Greig; Patrick Midoux; Chantal Pichon; Mohammad Amjad Kamal
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

2.  Cationic PAMAM dendrimers aggressively initiate blood clot formation.

Authors:  Clinton F Jones; Robert A Campbell; Amanda E Brooks; Shoeleh Assemi; Soheyl Tadjiki; Giridhar Thiagarajan; Cheyanne Mulcock; Andrew S Weyrich; Benjamin D Brooks; Hamidreza Ghandehari; David W Grainger
Journal:  ACS Nano       Date:  2012-10-24       Impact factor: 15.881

3.  Nanomedicine for prion disease treatment: new insights into the role of dendrimers.

Authors:  James M McCarthy; Dietmar Appelhans; Jörg Tatzelt; Mark S Rogers
Journal:  Prion       Date:  2013 May-Jun       Impact factor: 3.931

4.  Dendrimers and Polyamino-Phenolic Ligands: Activity of New Molecules Against Legionella pneumophila Biofilms.

Authors:  Elisa Andreozzi; Federica Barbieri; Maria F Ottaviani; Luca Giorgi; Francesca Bruscolini; Anita Manti; Michela Battistelli; Luigia Sabatini; Anna Pianetti
Journal:  Front Microbiol       Date:  2016-03-09       Impact factor: 5.640

5.  Inhibition of peptide aggregation by means of enzymatic phosphorylation.

Authors:  Kristin Folmert; Malgorzata Broncel; Hans V Berlepsch; Christopher Hans Ullrich; Mary-Ann Siegert; Beate Koksch
Journal:  Beilstein J Org Chem       Date:  2016-11-18       Impact factor: 2.883

Review 6.  Use of Polyamidoamine Dendrimers in Brain Diseases.

Authors:  Maria Florendo; Alexander Figacz; Bhairavi Srinageshwar; Ajit Sharma; Douglas Swanson; Gary L Dunbar; Julien Rossignol
Journal:  Molecules       Date:  2018-09-03       Impact factor: 4.411

Review 7.  Dendrimers as Antiamyloid Agents.

Authors:  Svetlana A Sorokina; Zinaida B Shifrina
Journal:  Pharmaceutics       Date:  2022-03-31       Impact factor: 6.525

8.  Synthetic Sulfated Polymers Control Amyloid Aggregation of Ovine Prion Protein and Decrease Its Toxicity.

Authors:  Pavel Semenyuk; Diana Evstafyeva; Vladimir Izumrudov; Vladimir Muronetz
Journal:  Polymers (Basel)       Date:  2022-04-05       Impact factor: 4.329

Review 9.  Advances on Therapeutic Strategies for Alzheimer's Disease: From Medicinal Plant to Nanotechnology.

Authors:  Nasser A Hassan; Asma K Alshamari; Allam A Hassan; Mohamed G Elharrif; Abdullah M Alhajri; Mohammed Sattam; Reham R Khattab
Journal:  Molecules       Date:  2022-07-28       Impact factor: 4.927

10.  Anti-prion drug mPPIg5 inhibits PrP(C) conversion to PrP(Sc).

Authors:  James M McCarthy; Markus Franke; Ulrike K Resenberger; Sibeal Waldron; Jeremy C Simpson; Jörg Tatzelt; Dietmar Appelhans; Mark S Rogers
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.